公司诉讼事件 - 股东在2024年3月7日至2025年3月3日期间购买PepGen Inc (NASDAQ: PEPG)股票可能受到公司虚假陈述影响 [3] - 诉讼指控公司未披露其主导产品PGN-EDO51的实际效果和安全性低于公司宣称水平 [3] - 公司CONNECT2二期研究存在缺陷可能无法获得FDA批准 [3] 产品研发问题 - 公司主导产品PGN-EDO51的临床效果和商业前景被夸大 [3] - CONNECT2研究可能因安全性和有效性不足而中止 [3] 法律程序 - 股东需在2025年8月8日前登记参与集体诉讼 [4] - 登记股东将获得案件进展监控服务 [4] - 申请成为首席原告的截止日期为2025年8月8日 [4]

诉讼背景 - 针对PepGen Inc (NASDAQ: PEPG)的证券集体诉讼由Levi & Korsinsky律师事务所发起 旨在为2024年3月7日至2025年3月3日期间因涉嫌证券欺诈而遭受损失的投资者追回损失 [1] 指控内容 - 公司主打产品PGN-EDO51的有效性和安全性低于管理层向投资者传达的水平 [2] - 第二阶段CONNECT2研究存在设计缺陷或安全隐患 可能无法满足美国食品药品监督管理局(FDA)的批准要求 [2] - 由于上述问题 公司可能暂停CONNECT2研究 且PGN-EDO51的临床、监管和商业前景被夸大 [2] - 公司在此期间发布的公开声明存在重大虚假和误导性陈述 [2] 程序安排 - 受影响投资者可在2025年8月8日前向法院申请作为首席原告参与诉讼 [3] - 集体诉讼成员无需支付任何自付费用即可参与赔偿申请 [3] 律所资质 - Levi & Korsinsky律师事务所过去20年为受损股东追回数亿美元资金 拥有70人以上的专业团队 [4] - 该律所连续七年被ISS证券集体诉讼服务评为美国前50大证券诉讼律师事务所之一 [4]

A lawsuit was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased or acquired the securities of PepGen between March 7, 2024 and March 3, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers. NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG ...

NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=152957&from=4CLASS PERIOD: March 7, 2024 to March 3, 2025 ...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and certain officers.   The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-03221, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, bot ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 15, 2025 /PRNewswire/ -- Fa ...

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025. SO WHAT: If you purchased PepGen securities during the Class Period you ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submissio ...

NEW YORK, June 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form ...

公司概况 - PepGen Inc 是一家临床阶段的生物技术公司 专注于开发用于治疗严重神经肌肉和神经系统疾病的寡核苷酸疗法 [1] - 公司的主要候选产品是 PGN-EDO51 这是一种专有的增强型寡核苷酸肽 用于治疗杜氏肌营养不良症 [1] 诉讼事件 - Robbins LLP 代表在2024年3月7日至2025年3月3日期间购买或收购PepGen证券的投资者提起了集体诉讼 [1] - 诉讼指控公司未能披露 PGN-EDO51 的有效性和安全性低于公司向投资者传达的水平 [2] - 诉讼还指控 CONNECT2 研究存在危险或缺陷 可能无法获得FDA批准 [2] - 由于上述原因 公司可能暂停CONNECT2研究 且PGN-EDO51的临床、监管和商业前景被夸大 [2] 临床研究问题 - 2025年1月29日 公司发布新闻稿 更新了CONNECT1研究中的安全问题 包括一名参与者的肾小球滤过率下降导致给药暂停 [3] - 加拿大卫生部要求公司提供更多信息以解决其安全担忧 然后才能继续进行剂量递增或招募更多参与者 [3] - 对于CONNECT2研究 公司正在与FDA合作解决其对计划剂量水平的支持数据的疑问 [3] - 2025年3月4日 公司宣布自愿暂停CONNECT2研究 直到可以审查CONNECT1研究中10 mg/kg队列的结果 [4] 市场反应 - 2025年1月30日 公司股价下跌0.40美元 跌幅21.74% 收于1.44美元 [3] - 2025年3月4日 公司股价进一步下跌0.53美元 跌幅18.86% 收于2.28美元 [4]